CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma.
- Authors
- Zheng, Xin; Song, Tao; Dou, Changwei; Jia, Yuli; Liu, Qingguang
- Year
- 2015
- Journal
- Oncotarget
- PMID
- 25686837
- DOI
- 10.18632/oncotarget.2915
- PMCID
- PMC4414151
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion. In this investigation, we showed thatCtBP2 expression was increased significantly in HCC tissues when compared to matched normal adjacent liver tissues. We also showed that CtBP2 expression is associated with worse HCC patient prognosis after liver resection. CtBP2 over-expression induced epithelial-mesenchymal transition (EMT) in Huh7 cells and, correspondingly, silencing CtBP2 suppressed EMT in MHCC97H cells. ChIP assays revealed that GLI1 increased CtBP2 transcription by directly binding its promoter. Furthermore, interaction of CtBP2 and Snail Family Zinc Finger 1 (SNAI1), both of which were found to be positively regulated by GLI1, was confirmed by Co-IP assay. SNAI1 knockdown revealed that SNAI1 was essential for CtBP2 induction of the EMT phenotype of HCC cells, and CtBP2 knockdown reversed GLI1-SNAI1 driven EMT in Huh7 cells. Finally, in vivo experiments demonstrated that enhanced CtBP2expression promoted HCC xenograft growth and induced EMT. In conclusion, CtBP2 may serve as a prognostic marker for post liver resection HCC and may play a role during GLI1-driven EMT as a transcriptional co-repressor of SNAI1.
CtBP2 expression was upregulated in HCC tissues and associated with poor prognosis after liver resection(A) CtBP2 was expressed mainly in the cytoplasm of tumor cells and CtBP2 expression was notably higher in HCC tissues (a) when compared to matched normal adjacent liver tissues (b). (B) The MannβWhitney U test confirmed that CtBP2 expression was significantly higher in HCC tissues than adjacent liver tissues from 100 HCC patients ( p < 0.001). (C) Kaplan Meier overall survival curves indicated that the High CtBP2 Group had an obviously shortened post-surgical survival time when compared to the Low CtBP2 Group (HR = 3.071; 95% CI: 1.357, 6.951; p = 0.007). (D) There was more GLI1 expression in HCC tissues (a) compared to matched normal adjacent liver tissues (b), and most of the GLI1-positive cells showed nuclear staining. (E) SNAI1 expression was notably increased in HCC tissues by IHC (a) when compared to matched adjacent healthy liver tissues (b). (F) The Spearman rank test indicated that GLI1 expression correlated positively with CtBP2 expression (r = 0.701, p < 0.001, left panel) and SNAI1 (r = 0.759, p < 0.001, right panel) in HCC tissues, respectively.
LLM interpretation
This figure consists of immunohistochemistry (IHC) images, a dot plot, a Kaplan-Meier survival curve, and scatter plots. IHC images (A, D, E) show higher expression of CtBP2, GLI1, and SNAI1 in HCC tissues compared to adjacent liver tissues, with the dot plot (B) confirming significantly higher CtBP2 IHC scores in HCC tissues (p < 0.001). The survival curve (C) indicates that high CtBP2 expression is associated with significantly shorter overall survival (p = 0.007, HR = 3.071). Scatter plots (F) demonstrate a significant positive correlation between GLI1 expression and both CtBP2 (r = 0.701, p < 0.001) and SNAI1 (r = 0.759, p < 0.001).
The expression of CtBP2 in HCC cell lines(A) CtBP2 mRNA levels in five different HCC cell lines was assessed by qRT-PCR. (B) CtBP2 protein expression in five different HCC cell lines was examined by Western blotting.
LLM interpretation
Figure A is a bar chart showing the CtBP2/18s mRNA ratio across five HCC cell lines, with the highest expression in MHCC97H and the lowest in Huh7. Figure B is a Western blot showing CtBP2 protein levels and $\beta$-actin as a loading control for the same five cell lines. Both visualizations demonstrate a consistent trend where CtBP2 expression is highest in PLC/PRF/5 and MHCC97H and lowest in Huh7 and Hep3B.
Elevated CtBP2 expression promoted Huh7 cell mobility and invasion by inducing EMT(A) Both qRT-PCR and Western blotting assays verified that CtBP2 expression was increased after stable transfection of CtBP2 expression plasmid. (B) The migration capacity of Huh7 cells, as assessed by wound healing assays, was enhanced by CtBP2 overexpression. (C) Transwell invasion assays demonstrated that elevating CtBP2 expression increased the invasive capability of Huh7 cells. (D) Overexpression of CtBP2 decreased E-cadherin expression and increased the expression of N-cadherin, Vimentin and Fibronectin in Huh7 cells, as measured by Western blotting. (E) Double immunofluorescence staining confirmed that CtBP2 overexpression resulted in the downregulation of E-cadherin and the upregulation of N-cadherin in Huh7 cells.
LLM interpretation
This figure consists of multiple panels demonstrating the effect of CtBP2 overexpression on Huh7 cells. Panels A, B, and C use Western blots, a bar chart (migration %), and a Transwell assay with a corresponding bar chart (cell number) to show that CtBP2 overexpression increases protein/mRNA levels and enhances cell migration and invasion ($P \le 0.003$). Panel D uses Western blotting to show that CtBP2 overexpression decreases E-cadherin while increasing N-cadherin, Vimentin, and Fibronectin. Panel E uses double immunofluorescence staining to visually confirm the downregulation of E-cadherin (green) and upregulation of N-cadherin (red) in CtBP2-overexpressing cells.
CtBP2 knockdown inhibited MHCC97H cell migration and invasion capacities by repressing EMT(A) Both qRT-PCR and Western blotting assays confirmed that siRNA transfection eliminated CtBP2 expression in MHCC97H cells. (B) Wound healing assays indicated that CtBP2 siRNA suppressed MHCC97H cell migration. (C) The invasive ability of MHCC97H cells was repressed by CtBP2 siRNA in Transwell invasion assays. (D) Western blotting assays demonstrated that CtBP2 suppression lead to E-cadherin upregulation and N-cadherin, Vimentin and Fibronectin downregulation in MHCC97H cells.
LLM interpretation
This figure consists of four panels (A-D) evaluating the effect of CtBP2 knockdown on MHCC97H cells. Panel A uses a Western blot and bar chart to show a significant decrease in CtBP2 protein and mRNA levels ($P < 0.001$) following CtBP2 siRNA transfection. Panels B and C utilize bar charts and microscopy images to demonstrate that CtBP2 knockdown significantly reduces cell migration at 24h and 48h ($P < 0.001$ and $P = 0.002$) and decreases the number of invading cells ($P < 0.001$). Panel D shows a Western blot where CtBP2 suppression leads to increased E-cadherin expression and decreased N-cadherin, Vimentin, and Fibronectin levels.
GLI1 increased CtBP2 expression directly by binding to its promoter(A) Both qRT-PCR and Western blotting assays demonstrated that the expression of GLI1 (left panel) and CtBP2 (right panel) were notably elevated after GLI1 overexpression in Huh7 cells. (B) A schematic model of the locations and sequences of the 14 potential GLI1 binding sites (BS). The consensus GLI1 binding sequence is listed here. (C) Luciferase reporter assays in Huh7 GLI1 cells indicate that the pGL3β1307 (β1307/β1 bp CtBP2 promoter fragment) has the strongest promoter activity. When the fragment between β1307 bp and β676 bp was deleted, the luciferase activity greatly reduced. The pGL3β1350 (β1350/β652 bp CtBP2 promoter fragment) displayed the second highest level of promoter activity. (D) Luciferase reporter assays demonstrated that the luciferase activity of pGL3β1350 was notably enhanced after GLI1 overexpression in Huh7 cells. This supports the ability of the GLI1 protein to bind the CtBP2 promoter in the β1350/β652 bp region. (E) DNA fragments capable of binding the GLI1 protein in the cell nucleus were analyzed by ChIP assay. As the upper panel shows, the PCR assay showed that the GLI1 protein was capable of directly binding to the β1350/β652 bp CtBP2 promoter fragment. After equalization using RNA Polymerase II (Input), more CtBP2 promoter fragment was bound to the GLI1 protein in Huh7 GLI1 cells. Similarly, a relative rtPCR assay demonstrated that elevated GLI1 expression increased the CtBP2 promoter occupancy of GLI1 in Huh7 cells, as presented in the lower panel.
LLM interpretation
This figure consists of five panels (A-E) demonstrating that GLI1 directly increases CtBP2 expression. Panel A uses Western blots and bar charts to show increased GLI1 and CtBP2 protein and mRNA levels in Huh7 GLI1 cells compared to Huh7 Vector controls ($P=0.006$ and $P<0.001$). Panel B provides a schematic of 14 potential GLI1 binding sites on the CtBP2 promoter, while Panels C and D use luciferase reporter assays to identify the $-1350/-652$ bp region as a key promoter area activated by GLI1 overexpression ($P=0.001$). Panel E utilizes a ChIP assay (PCR gel and bar chart) to confirm that GLI1 protein directly binds to the $-1350/-652$ bp CtBP2 promoter fragment, with a significant increase in enrichment in Huh7 GLI1 cells ($P=0.018$).
CtBP2 interacted with SNAI1 and played a critical role in GLI1/SNAI1 induction of EMT(A) Both qRT-PCR and Western blotting assays demonstrated that SNAI1 siRNA abated SNAI1 expression (left panel) in Huh7 cells and that CtBP2 expression was enhanced by CtBP2 expression plasmid transfection in Huh7 cells without SNAI1. (B) Western blotting showed that CtBP2 overexpression lead to E-cadherin downregulation and N-cadherin, Vimentin and Fibronectin upregulation in Huh7 cells with normal SNAI1 expression. However, silencing SNAI1 counteracted the regulatory effect of CtBP2 on E-cadherin, N-cadherin, Vimentin and Fibronectin. (C) Co-IP assays demonstrated direct CtBP2 and SNAI1 binding in Huh7 GLI1 cells. (D) Both qRT-PCR and Western blotting verified that siRNA abolished CtBP2 expression in Huh7 GLI1 cells. (E) Western blotting assays demonstrated that CtBP2 knockdown in Huh7 GLI1 cells lead to E-cadherin upregulation and N-cadherin, Vimentin and Fibronectin downregulation, while SNAI1 expression was not significantly affected. However, silencing CtBP2 did not affect the expression of E-cadherin, N-cadherin and Fibronectin. Neither the expression of Vimentin nor the expression of SNAI1 could be detected in Huh7 Vector cells transfected with CtBP2 siRNAs or Scr siRNAs.
LLM interpretation
This figure consists of Western blots, bar charts, and Co-IP assays analyzing the interaction between CtBP2 and SNAI1 in Huh7 cells. Panels A, B, D, and E use Western blotting and qRT-PCR to show that SNAI1 silencing reduces SNAI1 expression and counteracts CtBP2-induced EMT markers (downregulating N-cadherin, Vimentin, and Fibronectin while upregulating E-cadherin), while CtBP2 knockdown in GLI1 cells reverses these EMT markers without affecting SNAI1 levels. Panel C displays Co-IP assays demonstrating direct binding between CtBP2 and SNAI1. Statistical significance for mRNA expression changes in panels A and D is indicated as $P < 0.001$.
Elevated CtBP2 expression accelerated HCC xenograft growth and promoted EMT in HCC xenograft tissues(A) Representative pictures of HCC xenografts from both Huh7 Vector (left panel) and Huh7 CtBP2 cells (right panel). (B) Xenograft size in the Huh7 CtBP2 group was significantly larger than in the Huh7 Vector Group ( p = 0.001).
LLM interpretation
Figure A consists of representative photographs showing mice and excised HCC xenograft tumors from two groups: Huh7 Vector and Huh7 CtBP2. Figure B is a bar chart comparing the xenograft size ($\text{mm}^3$) between these two groups. The Huh7 CtBP2 group shows visibly larger tumors and a significantly higher mean xenograft size compared to the Huh7 Vector group ($p = 0.001$).
Compared to the Huh7 Vector group, there was more CtBP2 and N-cadherin protein expression in xenograft tissues from the Huh7 CtBP2 group, whereas E-cadherin expression was decreasedGLI1 and SNAI1 expression was undetected in xenograft tissues from either the Huh7 CtBP2 or the Huh7 Vector Group.
LLM interpretation
This figure consists of a panel of immunohistochemistry (IHC) images comparing protein expression in xenograft tissues from two groups: Huh7 Vector and Huh7 CtBP2. The rows are labeled by protein target (CtBP2, E-cadherin, N-cadherin, GLI1, and SNAI1), showing increased brown staining for CtBP2 and N-cadherin and decreased staining for E-cadherin in the Huh7 CtBP2 group compared to the Vector group. Staining for GLI1 and SNAI1 appears minimal or undetected across both experimental groups.
Working model of the role of CtBP2 in EMT induced by the GLI1/SNAI1 axis in HCCGLI1 upregulates both SNAI1 and CtBP2 simultaneously. SNAI1 binds the E-cadherin promoter after binding CtBP2, leading to the EMT phenotype of HCC cells.
LLM interpretation
This is a schematic diagram illustrating a proposed molecular mechanism for epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) cells. The model shows GLI1 upregulating the expression of both CtBP2 and SNAI1, which then form a complex that binds to the E-cadherin promoter to inhibit its expression. This pathway is depicted as leading to EMT, ultimately resulting in the migration and invasion of HCC cells.
| Name | Type |
|---|---|
| 18S ribosomal RNA local | gene |
| 7300 Real-Time PCR System local | drug |
| ABCG2 local | gene |
| ABI TaqMan Gene Expression assays local | drug |
| ACTB | gene |
| Adenovirus E1A protein local | drug |
| Advanced TNM staging local | phenotype |
| advanced tumor stages local | phenotype |
| Akt | gene |
| alcohol | phenotype |
| Alexa-Fluor-488 local | drug |
| Alexa-Fluor-555 local | drug |
| antibody local | drug |
| aprotinin | drug |
| BALB/c nude mice local | cohort |
| Basal cell carcinoma local | phenotype |
| breast cancer | phenotype |
| cancer progression local | phenotype |
| CAV1 | gene |
| CDH2 | gene |
| cell migration | phenotype |
| cell mobility local | phenotype |
| c-myc | gene |
| CO2 | drug |
| Colon cancer | phenotype |
| control plasmid local | drug |
| crystal violet | drug |
| CtBP1 local | gene |
| Ctbp2 | gene |
| CtBP2 expressing plasmid local | drug |
| CYLD | gene |
| DAPI | drug |
| diaminobenzidine local | drug |
| DMEM | drug |
| DNMTs | gene |
| Dual-Luciferase Reporter Assay System local | drug |
| E-cadherin | gene |
| Edmondson-Steiner classification local | phenotype |
| Edmondson-Steiner Classification local | phenotype |
| EDTA | drug |
| elevated serum PSA levels local | phenotype |
| EMT | phenotype |
| EZ-Magna ChIPTM Chromatin Immunoprecipitation Kit local | drug |
| fetal bovine serum | drug |
| Fibronectin local | gene |
| First Affiliated Hospital of Xi'an Jiaotong University HCC cohort local | cohort |
| formaldehyde | drug |
| Gastric cancer | phenotype |
| GLI1 local | gene |
| GLI1 expressing plasmid local | drug |
| glycerol | drug |
| HCC | phenotype |
| HCC cells local | cohort |
| HCC patient cohort (n=100) local | cohort |
| HCC patients local | cohort |
| HCC recurrence local | phenotype |
| HCC tissues local | cohort |
| HCC xenograft model local | cohort |
| hematoxylin | drug |
| Hep3B local | cohort |
| hepatocellular carcinoma | phenotype |
| Hepatocellular carcinoma cells local | phenotype |
| HepG2 | cohort |
| High Capacity cDNA Reverse Transcription kit | drug |
| High CtBP2 Group local | cohort |
| higher Gleason scores local | phenotype |
| Huh7 local | cohort |
| Huh7 cells local | cohort |
| Huh7 CtBP2 local | cohort |
| Huh7 CtBP2 cells local | cohort |
| Huh7 Vector local | cohort |
| Huh7 Vector cells local | cohort |
| hydrogen peroxide | drug |
| IgG local | drug |
| invasion | phenotype |
| leupeptin | drug |
| Low CtBP2 Group local | cohort |
| luciferase | drug |
| matrigel | drug |
| Medulloblastoma local | phenotype |
| MEM medium local | drug |
| metastatic dissemination local | phenotype |
| MHCC97H local | cohort |
| migration | phenotype |
| normal goat serum | drug |
| normal rabbit IgG local | drug |
| NP-40 | drug |
| outcome | phenotype |
| ovarian tumor local | phenotype |
| overall survival | phenotype |
| p16Ink4a | gene |
| Pancreatic carcinoma local | phenotype |
| paraffin | drug |
| patient outcome local | phenotype |
| Patient outcome after HCC surgery local | phenotype |
| patient prognosis local | phenotype |
| pCMV-Tag2B vector local | drug |
| pGL3-1350 reporter plasmid local | drug |
| PIPES buffer local | drug |
| PLC/PRF/5 local | cohort |
| PMSF | drug |
| Poor overall postsurgical survival local | phenotype |
| poor prognosis | phenotype |
| primary liver cancer subtype local | phenotype |
| prostate cancer | phenotype |
| protein A/G-agarose beads local | drug |
| PTEN | gene |
| REG4 local | gene |
| RIPA buffer | drug |
| RNA Polymerase II local | gene |
| RPMI 1640 medium local | drug |
| Serum-free medium local | drug |
| siRNA | drug |
| SNAI1 | gene |
| sodium citrate buffer local | drug |
| sodium fluoride local | drug |
| sodium vanadate local | drug |
| SYBR Green PCR Master Mix local | drug |
| TNM stage local | phenotype |
| TNM staging local | phenotype |
| Tris-HCl | drug |
| Triton X-100 | drug |
| Trizol | drug |
| tumor growth | phenotype |
| Tumor recurrence local | phenotype |
| tumor size local | phenotype |
| Tumor size local | phenotype |
| Venous infiltration local | phenotype |
| VIM | gene |
| xylene | drug |
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A genome wide association study of fast beta EEG in families of European ancestry. | 2017 | 28040410 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| The role of the CTBP2 mediated glycolytic pathway in nasopharyngeal carcinoma metastasis. | Lin Y et al. | β | 2026 | β |
| Retraction: Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. | Liu Z et al. | β | 2025 | β |
| A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma. | Craig O et al. | β | 2024 | β |
| Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. | Zhang T et al. | β | 2024 | β |
| C-Terminal Binding Protein: Regulator between Viral Infection and Tumorigenesis. | Huang M et al. | β | 2024 | β |
| "GLI1 Subcellular Localization and Overexpression as Prognostic Factors for Disease-Free Survival in Colorectal Carcinoma". | Rather TB et al. | β | 2024 | β |
| Relationship between cancer stem cell-related SNPs and survival outcomes in patients with primary lung cancer. | Xu X et al. | β | 2023 | β |
| Cryo-EM structure of CtBP2 confirms tetrameric architecture. | Jecrois AM et al. | β | 2021 | β |
| CtBP modulates Snail-mediated tumor invasion in Drosophila. | Wu C et al. | β | 2021 | β |
| Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. | Koo SC et al. | β | 2021 | β |
| GLI1: A Therapeutic Target for Cancer. | Avery JT et al. | β | 2021 | β |
| NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP). | Nichols JC et al. | β | 2021 | β |
| Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells. | Parfenyev SE et al. | β | 2021 | β |
| CryoEM Structure of CtBP2 Confirms Tetrameric Architecture | Jecrois AM et al. | β | 2020 | β |
| CtBP2 interacts with ZBTB18 to promote malignancy of glioblastoma. | Chen L et al. | β | 2020 | β |
| C-terminal binding protein-2 is a prognostic marker for lung adenocarcinomas. | Li B et al. | β | 2020 | β |
| C-terminal of E1A binding protein 2 promotes the malignancy of osteosarcoma cells via JAK1/Stat3 signaling. | Wang P et al. | β | 2020 | β |
| Stabilization of C-terminal binding protein 2 by cellular inhibitor of apoptosis protein 1 via BIR domains without E3 ligase activity. | Seo TW et al. | β | 2020 | β |
| C-terminal of E1A binding protein 1 enhances the migration of gastric epithelial cells and has a clinicopathologic significance in human gastric carcinoma. | Wang C et al. | β | 2019 | β |
| SNP-SNP and SNP-environment interactions of potentially functional HOTAIR SNPs modify the risk of hepatocellular carcinoma. | Zhang J et al. | β | 2019 | β |
| TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma. | Wang C et al. | β | 2019 | β |
| Assembly of human C-terminal binding protein (CtBP) into tetramers. | Bellesis AG et al. | β | 2018 | β |
| HBV Upregulates CtBP2 Expression via the X Gene. | Liu X et al. | β | 2018 | β |
| PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. | Peng Y et al. | β | 2018 | β |
| A genome wide association study of fast beta EEG in families of European ancestry. | Meyers JL et al. | β | 2017 | β |
| CtBP2 ameliorates palmitate-induced insulin resistance in HepG2 cells through ROS mediated JNK pathway. | Liu P et al. | β | 2017 | β |
| CtBP2 overexpression promotes tumor cell proliferation and invasion in gastric cancer and is associated with poor prognosis. | Dai F et al. | β | 2017 | β |
| CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors. | Dcona MM et al. | β | 2017 | β |
| Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro. | Nan J et al. | β | 2017 | β |
| EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling. | Xu M et al. | β | 2017 | β |
| FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3Ξ² - dependent manner in hepatocellular carcinoma. | Yang W et al. | β | 2017 | β |
| LncRNA NEAT1 Regulates Cell Viability and Invasion in Esophageal Squamous Cell Carcinoma through the miR-129/CTBP2 Axis. | Li Y et al. | β | 2017 | β |
| MiR-338 suppresses cell proliferation and invasion by targeting CTBP2 in glioma. | Liu DZ et al. | β | 2017 | β |
| BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. | Xu M et al. | β | 2016 | β |
| Down-regulation of the zinc-finger homeobox protein TSHZ2 releases GLI1 from the nuclear repressor complex to restore its transcriptional activity during mammary tumorigenesis. | Riku M et al. | β | 2016 | β |
| In vitro three dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents. | Shrum B et al. | β | 2016 | β |
| RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. | Wang C et al. | β | 2016 | β |
| Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance. | Palle K et al. | β | 2015 | β |